STCube and Samsung Biologics announced an additional strategic development and manufacturing service agreement for STM418 antibody, an anti-PD1 immuno-oncology candidate.

STM418 received much attention from the biopharma industry earlier this year upon publication in the Cancer Research Journal. Noting that the glycosylation site N58 on PD-1 plays a crucial role in PD-1/PD-L1 binding, STCube reported that STM418, which selectively masks N58 on PD-1, may work more effectively than other FDA-approved anti-PD1 agents through preliminary studies.

Under the development and manufacturing agreement, Samsung Biologics will offer full scope of CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418.

“We look forward to getting fast IND approval for our novel PD-1 antibody through this extended partnership with Samsung Biologics, a world-class CDMO," said Hyun-jin Jung, CEO of STCube. "We will commence global clinical trials to prove the enhanced efficacy compared to existing PD-1 antibodies.” <End>

About STCube, Inc.

STCube, Inc. (KRX: 052020.KQ), headquartered in Seoul, South Korea, is an innovative global biopharmaceutical company devoted to developing the next generation of anti-cancer immunotherapy. For more information, visit www.stcube.com